A randomised placebo-controlled Phase III multicentre trial: low-dose intravenous immunoglobulin treatment for long-standing complex regional pain syndrome (LIPS trial)

Andreas Goebel,1* Jatinder Bisla,2 Roy Carganillo,3 Claire Cole,1 Bernhard Frank,4 Rima Gupta,5 Mairi James,6 Joanna Kelly,2 Candy McCabe,7,8 Holly Milligan,1 Caroline Murphy,2 Nick Padfield,3 Ceri Phillips,9 Helen Poole,10 Mark Saunders,11 Mick Serpell,6 Nick Shenker,12 Karim Shoukrey,13 Lynne Wyatt4 and Gareth Ambler14

1Pain Research Institute, Clinical Sciences Centre, Liverpool, UK
2King’s Clinical Trials Unit, Institute of Psychiatry, Psychology and Neuroscience, London, UK
3Pain Management and Neuromodulation Centre, Guy’s and St Thomas’ Hospital, London, UK
4The Walton Centre NHS Foundation Trust, Liverpool, UK
5Modepharma Ltd, Beckenham, UK
6University Department of Anaesthesia, Queen Elizabeth University Hospital, Glasgow Clinical Research Facility, Glasgow, UK,
7Royal National Hospital for Rheumatic Diseases, Bath, UK
8University of the West of England, Bristol, UK
9College of Human and Health Sciences, Swansea University, Swansea, UK
10Faculty of Science, Liverpool John Moores University, Liverpool, UK
11Norfolk and Norwich University NHS Trust, Norwich, UK
12Department of Rheumatology, Cambridge University Hospitals, Cambridge, UK,
13University Hospital of Leicester NHS Trust, Leicester General Hospital, Leicester, UK
14Statistical Science, University College London, London, UK

*Corresponding author andreasgoebel@rocketmail.com/andreas.goebel@liv.ac.uk
Declared competing interests of authors: Andreas Goebel reports grants from the National Institute for Health Research (NIHR) Medical Research Council (MRC) Efficacy and Mechanism Evaluation (EME) programme, other funds from Biotest AG, Germany, and grants from Biotest AG during the conduct of the study. Furthermore, he received personal fees from Biotest AG and Axsome Therapeutics outside the submitted work. Mick Serpell reports grants from NIHR EME programme (a MRC and NIHR partnership), grants for additional funding obtained by the Pain Relief Foundation Liverpool, and non-financial support was received from Biotest UK Ltd, which provided the active study medication at no cost during the study. He has also received research support, consulting fees or honoraria in the past 3 years from Astellas Pharma, Grünenthal Ltd, NAPP and Pfizer. Nick Shenker reports NIHR funding for researchers’ time during the conduct of the study.

Published November 2017
DOI: 10.3310/eme04050

Scientific summary

The LIPS trial
Efficacy and Mechanism Evaluation 2017; Vol. 4: No. 5
DOI: 10.3310/eme04050

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

The text in the Scientific summary includes minor additions and formatting changes to the original text as published in Goebel A, Shenker N, Padfield N, Shoudrey K, McCabe C, Serpell M, et al. Low-dose intravenous immunoglobulin treatment for complex regional pain syndrome (CRPS): study protocol for a randomized controlled trial. *Trials* 2014;15:404. © Goebel et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Background

Complex regional pain syndrome (CRPS) is post-traumatic pain in a limb, and is associated with sensory, motor, autonomic, skin and bone changes. CRPS can resolve spontaneously, but if spontaneous resolution does not occur early, it is less likely to occur later. Many patients with CRPS have no effective method to relieve their ongoing pain. Those patients with CRPS of moderate to severe pain intensity were the target group for this study and report, on average, a very poor quality of life (QoL) and usually cannot work. Immunoglobulin treatment for chronic pain is a novel technology [Goebel A. Immunoglobulin responsive chronic pain. *J Clin Immunol* 2010;30(Suppl. 1):103–8]. In a first, open trial we found that low-dose intravenous immunoglobulin (IVIg) may be effective in reducing pain for some patients with CRPS (n = 11 participants; n = 3 had > 70% pain relief, n = 2 had > 25%< 70%, and n = 6 had 0–25% relief, following a variable number of low-dose infusion repeats). We later showed that, in one patient, repeat treatments provided reproducible effects. In a UK single-centre crossover randomised placebo controlled trial, a single, low-dose (0.5 g/kg) infusion of IVIg significantly reduced pain in patients with CRPS (n = 13, pain intensity on a validated 11-point Numeric Rating Scale (NRS) higher than 4 points (0 = no pain, 10 = pain as bad as you can imagine (Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain* 2005;113:9–19)]; these patients had the disease for between 0.5 and 2.5 years. The treatment difference was 1.55 NRS points [95% confidence interval (CI) 1.29 to 1.82 points; *p* < 0.001]. In a responder analysis (12 patients had received treatment), three patients had > 50% less pain (4.5, 5 and 5 NRS points) after IVIg when compared with after saline treatment, and two patients had 29% and 31% less pain (2 and 2.5 NRS points less pain). One patient had 25% less pain (2 NRS points less pain) after saline than those patients having IVIg treatment. The average effect duration was 5 weeks. There was also a significant overall reduction of CRPS-related, non-painful symptoms and, in responders, improved sleep and global improvement, with few adverse events (headaches and pain increases for < 3 days). Post-infusion questionnaires showed successful blinding of patients and study doctors. The above evidence provided proof of concept for the efficacy of low-dose immunoglobulin treatment for moderate and severe CRPS in reducing pain, with an advantageous side effect profile. The data also suggested that this treatment may improve QoL and pain interference. Because the numbers of treated patients were small, and most research was conducted in a single centre, it was important to confirm these findings in a larger group of patients and across several centres to gain confidence about both efficacy and affect size of this novel technology, and to demonstrate its generalisability.

Objectives

The primary objective was to gain, within 44 months, both definite proof of the clinical efficacy and a more confident estimate of the effect size of low-dose IVIg treatment to reduce pain in patients with moderate or severe CRPS.
Secondary objectives

To achieve better understanding of this technology, including:

- stability of effect with repeat administration
- factors predicting a beneficial response
- effects on additional outcome parameters including stimulus evoked pain, pain interference, QoL and short-term risk profile
- health economics evaluation
- creation of a bank of biological samples at the University of Liverpool for future CRPS serum autoantibody and serum substances research.

Methods (design/study population/participants/consent/randomisation/interventions/outcome measures)

We conducted a multicentre, randomised, double-blind, placebo-controlled, parallel group trial with an open extension across seven UK pain management centres. Patients were eligible if they had moderate or severe long-standing CRPS that they had experienced for up to 5 years. Participants were randomly allocated to receive 0.5 g/kg IVIg, the active intervention, or visually indistinguishable 0.1% albumin in saline placebo. Randomisation was initiated by study sites via an independent online randomisation system, and was 1:1 with varying block sizes, stratified by study centre. Participants, investigators and assessors were blinded to group assignment. The study drug/placebo was infused intravenously at the study centres on day 1 and day 22 after randomisation. The primary outcome was the 24-hour average pain intensity between day 6 and day 42, on an 11-point (0–10) NRS, compared between the groups. All patients who received an infusion and provided any outcome were included into the intention-to-treat analysis.

Results

A total of 111 patients were recruited and assigned between 27 August 2013 and 28 October 2015. Three patients were excluded because they had been inappropriately randomised, five patients were withdrawn from the primary analysis because they provided no outcomes and 103 patients were analysed for the primary outcome. The average pain score in the IVIg group was 0.27 units (95% CI –0.24 to 0.80 units) higher than in the placebo group. The 95% CI includes 0 and the corresponding p-value is relatively large (p = 0.30). Therefore, there is no significant evidence of a treatment effect at the 5% level and there was no significant difference between groups.

Limitations

Patients who had the disease for < 1 year and > 5 years were excluded from the study. Dosing was limited to a low-dose IVIg infusion at 0.5 g/kg. A second active arm with high-dose treatment would have been desirable.

Conclusions and recommendation for research

Low-dose immunoglobulin was not effective in relieving pain in patients with moderate to severe CRPS of 1–5 years’ duration. Better drug treatments for long-standing CRPS are urgently required.
**Trial registration**

This trial is registered as ISRCTN42179756.

**Funding**

This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research partnership. Additional funding was obtained by the Pain Relief Foundation. The funders of the study had no role in the study design, data collection, data analysis, data interpretation or writing of the report. Biotest UK Ltd provided the active study medication at no cost but had no other input into the design or implementation of the study and did not participate in the preparation of this publication.
Criteria for inclusion in the Efficacy and Mechanism Evaluation journal

Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme was set up in 2008 as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is broadly aimed at supporting ‘science driven’ studies with an expectation of substantial health gain and aims to support excellent clinical science with an ultimate view to improving health or patient care.

Its remit includes evaluations of new treatments, including therapeutics (small molecule and biologic), psychological interventions, public health, diagnostics and medical devices. Treatments or interventions intended to prevent disease are also included.

The EME programme supports laboratory based or similar studies that are embedded within the main study if relevant to the remit of the EME programme. Studies that use validated surrogate markers as indicators of health outcome are also considered.

For more information about the EME programme please visit the website: http://www.nets.nihr.ac.uk/programmes/eme

This report

The research reported in this issue of the journal was funded by the EME programme as project number 11/14/33. The contractual start date was in December 2012. The final report began editorial review in August 2016 and was accepted for publication in April 2017. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2017. This work was produced by Goebel et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Efficacy and Mechanism Evaluation Editor-in-Chief

Professor David Crossman  Bute Professor of Medicine and Dean and Head of Faculty of Medicine, University of St Andrews, and Honorary Consultant Cardiologist, NHS Fife Health Board, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Director of the NIHR Dissemination Centre, University of Southampton, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk